Controlled Fusion Protein, Tumor Microenvironment Drug Release, Stable Conjugation

Syndivia is at the forefront of cancer treatment innovation with its proprietary GeminiMab™ Technology, which focuses on the development of site-specific antibody-drug conjugates (ADCs). This unique platform allows for the precise conjugation of drugs to antibodies at the hinge region, specifically at the Cys229 site. By ensuring optimal drug-to-antibody ratios (DAR), including unique configurations like DAR1, DAR2, and DAR4, GeminiMab™ enhances the therapeutic efficacy of ADCs while maintaining the integrity and flexibility of the antibodies. This technology eliminates the need for complex modifications or pretargeting units, resulting in conjugates that preserve their native glycosylation profile and minimize potential immunogenicity.

Syndivia's commitment to advancing cancer therapies is further demonstrated through its proprietary pipeline of ADC candidates, which are designed to target various cancer types effectively. The company is actively developing ADCs that leverage the GeminiMab™ platform to achieve maximum efficacy with minimal safety concerns. Their pipeline includes promising candidates such as SDV2102, targeting PSMA for metastatic castration-resistant prostate cancer, and SDV2103, targeting TROP-2 for metastatic breast cancer. Syndivia's strategic partnerships and ongoing research efforts underscore its dedication to addressing the challenges of treating solid tumors and improving outcomes for patients with difficult-to-treat cancer indications.

France

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy.

Syndivia

Company Details